



**IOptima (Subsidiary) : Renewal of its regulatory approval for marketing and selling the IOptiMate™ System in China**

Tel Aviv (August 27<sup>th</sup>, 2018) – BioLight is pleased to announce that today, its subsidiary IOptima Ltd., ("IOptima")<sup>1</sup>, announced receipt of a renewal of its regulatory approval for marketing and selling the IOptiMate™ System in China, from the Chinese Food and Drug Administration ("CFDA"), for a period of 5 years until 2023.

IOptima has a distribution agreement in China with the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co with whom a final and binding agreement for the investment in and the acquisition in stages of IOptima was signed on November 2017.

---